Disease Molecular News Today : Breaking News, Live Updates & Top Stories | Vimarsana

/PRNewswire/ EpicentRx, a late clinical stage biopharmaceutical company with novel therapies to target cancer and inflammatory diseases, announced it will.

United statesSan diegoPrnewswire epicentrxEpicentrx cyInflammasome therapeutics summitControl numberDisease molecularProtects against inflammasome drivenProof of concept trialsVarious disease groupsClinical relevance